Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Stock Information for Cytek Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytek Biosciences Inc.

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY(TM) Sildenafil Cream
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY(TM) Difference - The Sildenafil Cream That Raises the Bar
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré's DARE to PLAY Sildenafil Cream
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.